ELAN CORP (DRX.IR)
-Irish 8.88 
0.12(1.36%) May 17, 11:30AM EDT
| Prev Close: | 8.76 |
|---|
| Open: | 8.83 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 8.83 - 8.93 |
|---|
| 52wk Range: | 7.29 - 12.01 |
|---|
| Volume: | 244,500 |
|---|
| Avg Vol (3m): | 373,379 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in EUR.
Headlines
- SAC Capital won't fully cooperate with government: letterReuters(Fri, May 17)
- SAC Capital won't fully cooperate with govt -letterat Reuters(Fri, May 17)
- Elan says Royalty wanted to take it private before Tysabri dealat Reuters(Wed, May 15)
- ADR REPORT-Japanese ADRs rise 1 pct on yen weaknessat Reuters(Mon, May 13)
- Elan-Theravance deal a big boost for Baupost, Fidelityat Reuters(Mon, May 13)
- Stocks to Watch: Theravance, Endo Health, Perion Networkat The Wall Street Journal(Mon, May 13)
- US STOCKS-Wall St set to dip at open after record highat Reuters(Mon, May 13)
- Elan's $1 billion drug royalty deal aids bid defenseReuters(Mon, May 13)
- Elan CEO says shareholders unmoved by Royalty bidReuters(Mon, May 13)
- US STOCKS-Futures dip after record high; retail sales on tapat Reuters(Mon, May 13)
- [$$] Elan Signs $1 Billion Drug Dealat The Wall Street Journal(Mon, May 13)
- Elan strikes $1 billion royalty deal with Theravanceat Reuters(Mon, May 13)
- Elan strikes $1 bln royalty deal with Theravanceat Reuters(Mon, May 13)
- BRIEF-Elan agrees $1 bln royalty deal with Theravanceat Reuters(Mon, May 13)
- Insider-trading trial of SAC Capital's Steinberg to start November 18Reuters(Fri, May 3)
Reports
- No Reports available for DRX.IR at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
()
: | N/A |
|---|
| Quarterly EPS Est
()
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
No business summary available forDRX.IR.